CLEVELAND, Sept. 30, 2013 /PRNewswire/ -- D ATATRAK International, Inc. (OTCQX: DTRK), a leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced it will be participating in DIA and BIAS events during the month of October.
Drug Information Association's 7 th Annual Clinical Forum Dublin, Ireland October 8-9, 2013Booth #26BConvention Centre Dublin
D ATATRAK will exhibit at the Forum and its Product Marketing Manager, Niki Kutac, will speak on "When Outsourcing – Technology and Procedures around the Technology are both Important" on October 8 th at 9:00 AM. The Forum's theme is Rebooting Clinical Development as Europe enters a new era in Clinical Development.10 th Latin American Conference of Clinical Research (LACCR) Sao Paulo, Brazil October 20-22, 2013 Maksoud Plaza D ATATRAK will attend DIA's LACCR 2013, which focuses on The Role of Clinical Research in the Future of Medicine. LACCR serves as the premier educational event in clinical research across Latin America, providing the latest information on current hot topics. DIA organized the event in partnership with the Sociedade Brasileira de Medicina Farmaceutica (SBMF), to address the role of clinical research in the future of medicine. V BIAS Annual Congress Milan, Italy October 24-25, 2013Bicocca University D ATATRAK's Vice President of Clinical and Consulting Services, Dr. Bill Gluck, will be speaking at the Biometristi dell'Industria Associati's V BIAS Annual Congress. The congress provides a forum for Italian Data Managers and Statisticians to discuss statistical and data issues in regulatory submissions. Dr. Gluck will be sharing his expertise on Risk-Based Monitoring in his presentation "Supporting Risk-Based Approaches to Clinical Monitoring from a CDM Perspective." Join D ATATRAK Thought Leaders: http://bit.ly/15DJjjX About D ATATRAK D ATATRAK International is a worldwide technology and services company delivering unified eClinical® solutions and related services for the clinical trials industry. D ATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via D ATATRAK's Clinical and Consulting Services group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The D ATATRAK ONE™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I – Phase IV drug and device studies in multiple languages throughout the world. D ATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit http://www.datatrak.com. Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on August 12, 2013 announcing its results for the second quarter of 2013. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise. SOURCE DATATRAK International, Inc.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts